Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients.

Acute disseminated encephalomyelitis (ADEM) Antibodies Cerebrospinal fluid Encephalomyelitis Lumbar puncture MOG antibody-associated disease (MOGAD) Multiple sclerosis (MS) Myelin oligodendrocyte glycoprotein (MOG) Neuromyelitis optica (Devic syndrome) Oligoclonal bands Optic neuritis Transverse myelitis

Journal

Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974

Informations de publication

Date de publication:
03 Sep 2020
Historique:
received: 08 11 2019
accepted: 23 04 2020
entrez: 5 9 2020
pubmed: 5 9 2020
medline: 22 7 2021
Statut: epublish

Résumé

New-generation cell-based assays have demonstrated a robust association of serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis, and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like or acute-disseminated encephalomyelitis (ADEM)-like presentations. However, only limited data are yet available on cerebrospinal fluid (CSF) findings in MOG-IgG-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD). To describe systematically the CSF profile in MOG-EM. Cytological and biochemical findings (including white cell counts and differentiation; frequency and patterns of oligoclonal bands; IgG/IgM/IgA and albumin concentrations and CSF/serum ratios; intrathecal IgG/IgA/IgM fractions; locally produced IgG/IgM/IgA concentrations; immunoglobulin class patterns; IgG/IgA/IgM reibergrams; Link index; measles/rubella/zoster (MRZ) reaction; other anti-viral and anti-bacterial antibody indices; CSF total protein; CSF L-lactate) from 163 lumbar punctures in 100 adult patients of mainly Caucasian descent with MOG-EM were analyzed retrospectively. Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in almost 90% of samples (N = 151), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (N = 62). If present, intrathecal IgG (and, more rarely, IgM) synthesis was low, often transient and mostly restricted to acute attacks. CSF WCC was elevated in > 50% of samples (median 31 cells/μl; mostly lymphocytes and monocytes; > 100/μl in 12%). Neutrophils were present in > 40% of samples; activated lymphocytes were found less frequently and eosinophils and/or plasma cells only very rarely (< 4%). Blood-CSF barrier dysfunction (as indicated by an elevated albumin CSF/serum ratio) was present in 48% of all samples and at least once in 55% of all patients (N = 88) tested. The frequency and degree of CSF alterations were significantly higher in patients with acute myelitis than in patients with acute ON and varied strongly depending on attack severity. CSF L-lactate levels correlated significantly with the spinal cord lesion load in patients with acute myelitis (p < 0.0001). Like pleocytosis, blood-CSF barrier dysfunction was present also during remission in a substantial number of patients. MOG-IgG-positive EM is characterized by CSF features that are distinct from those in MS. Our findings are important for the differential diagnosis of MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease.

Sections du résumé

BACKGROUND BACKGROUND
New-generation cell-based assays have demonstrated a robust association of serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis, and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like or acute-disseminated encephalomyelitis (ADEM)-like presentations. However, only limited data are yet available on cerebrospinal fluid (CSF) findings in MOG-IgG-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD).
OBJECTIVE OBJECTIVE
To describe systematically the CSF profile in MOG-EM.
MATERIAL AND METHODS METHODS
Cytological and biochemical findings (including white cell counts and differentiation; frequency and patterns of oligoclonal bands; IgG/IgM/IgA and albumin concentrations and CSF/serum ratios; intrathecal IgG/IgA/IgM fractions; locally produced IgG/IgM/IgA concentrations; immunoglobulin class patterns; IgG/IgA/IgM reibergrams; Link index; measles/rubella/zoster (MRZ) reaction; other anti-viral and anti-bacterial antibody indices; CSF total protein; CSF L-lactate) from 163 lumbar punctures in 100 adult patients of mainly Caucasian descent with MOG-EM were analyzed retrospectively.
RESULTS RESULTS
Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in almost 90% of samples (N = 151), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (N = 62). If present, intrathecal IgG (and, more rarely, IgM) synthesis was low, often transient and mostly restricted to acute attacks. CSF WCC was elevated in > 50% of samples (median 31 cells/μl; mostly lymphocytes and monocytes; > 100/μl in 12%). Neutrophils were present in > 40% of samples; activated lymphocytes were found less frequently and eosinophils and/or plasma cells only very rarely (< 4%). Blood-CSF barrier dysfunction (as indicated by an elevated albumin CSF/serum ratio) was present in 48% of all samples and at least once in 55% of all patients (N = 88) tested. The frequency and degree of CSF alterations were significantly higher in patients with acute myelitis than in patients with acute ON and varied strongly depending on attack severity. CSF L-lactate levels correlated significantly with the spinal cord lesion load in patients with acute myelitis (p < 0.0001). Like pleocytosis, blood-CSF barrier dysfunction was present also during remission in a substantial number of patients.
CONCLUSION CONCLUSIONS
MOG-IgG-positive EM is characterized by CSF features that are distinct from those in MS. Our findings are important for the differential diagnosis of MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease.

Identifiants

pubmed: 32883348
doi: 10.1186/s12974-020-01824-2
pii: 10.1186/s12974-020-01824-2
pmc: PMC7470615
doi:

Substances chimiques

Autoantibodies 0
Immunoglobulins 0
Myelin-Oligodendrocyte Glycoprotein 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

261

Subventions

Organisme : Dietmar Hopp Stiftung
ID : n/a
Organisme : Merck Serono Germany
ID : n/a
Organisme : German Federal Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
ID : n/a
Organisme : German Federal Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
ID : n/a
Organisme : German Federal Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
ID : n/a
Organisme : Deutsche Forschungsgemeinschaft (DFG Exc 257)
ID : n/a
Organisme : Deutsche Forschungsgemeinschaft
ID : n/a
Organisme : Baden-Württemberg Ministry of Science, Research and the Arts
ID : n/a
Organisme : Ruprecht-Karls-Universität Heidelberg
ID : n/a
Organisme : Jubilaeumsfonds of the Austrian National Bank
ID : 14158 and 15918

Références

Int J Mol Sci. 2016 Sep 21;17(9):
pubmed: 27657060
Neurology. 1999 Sep 22;53(5):1107-14
pubmed: 10496275
J Neuroinflammation. 2013 Jan 15;10:8
pubmed: 23320783
Mult Scler. 2009 Dec;15(12):1466-80
pubmed: 19995844
Ann Neurol. 2006 Mar;59(3):566-9
pubmed: 16453327
J Neuroinflammation. 2016 Nov 1;13(1):282
pubmed: 27802824
Arthritis Rheum. 2010 Apr;62(4):1198-200
pubmed: 20131265
J Neuroinflammation. 2019 Dec 28;16(1):280
pubmed: 31883522
J Neuroinflammation. 2012 Jan 19;9:14
pubmed: 22260418
Dtsch Med Wochenschr. 1979 Apr 13;104(15):553-7
pubmed: 436627
Neurology. 2014 Feb 11;82(6):474-81
pubmed: 24415568
Neurology. 2004 Dec 28;63(12):2363-70
pubmed: 15623701
Neurol Neuroimmunol Neuroinflamm. 2016 Apr 20;3(3):e231
pubmed: 27144221
J Neurol Sci. 1994 Apr;122(2):189-203
pubmed: 8021703
J Neurol Sci. 2019 Dec 15;407:116396
pubmed: 31726278
Nervenarzt. 2018 Dec;89(12):1388-1399
pubmed: 30264269
Ther Adv Neurol Disord. 2018 Mar 29;11:1756286418762083
pubmed: 29623106
Clin Chem Lab Med. 2010 May;48(5):659-63
pubmed: 20184532
J Neuroinflammation. 2018 Jan 18;15(1):22
pubmed: 29347989
Brain. 2008 Nov;131(Pt 11):3072-80
pubmed: 18945724
J Neurol. 2017 Mar;264(3):453-466
pubmed: 28005176
J Exp Med. 1986 Jan 1;163(1):41-53
pubmed: 3941297
J Neuroinflammation. 2016 Nov 1;13(1):281
pubmed: 27802825
Front Neurol. 2018 Oct 23;9:888
pubmed: 30405519
Acta Neurol Scand. 1988 Jul;78(1):6-9
pubmed: 3176884
Clin Exp Immunol. 2014 May;176(2):149-64
pubmed: 24666204
J Gen Physiol. 1992 Aug;100(2):341-67
pubmed: 1402785
Med Hypotheses. 2013 Dec;81(6):1090-5
pubmed: 24182872
Neurosci Lett. 1988 Apr 12;86(3):296-300
pubmed: 3380321
Brain. 2007 May;130(Pt 5):1235-43
pubmed: 17449477
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Arch Neurol. 1967 May;16(5):492-6
pubmed: 6022530
Brain. 2002 Jul;125(Pt 7):1450-61
pubmed: 12076996
Neurol Neuroimmunol Neuroinflamm. 2015 Jan 22;2(1):e62
pubmed: 25635259
Arch Neurol. 2007 Dec;64(12):1802; author reply 1802-3
pubmed: 18071052
Curr Opin Neurol. 2017 Jun;30(3):295-301
pubmed: 28248700
Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257
pubmed: 27458601
Am J Med. 1995 Aug;99(2):153-63
pubmed: 7625420
J Exp Med. 2008 Oct 27;205(11):2473-81
pubmed: 18838545
Mult Scler. 2016 Oct;22(12):1541-1549
pubmed: 26869529
Arch Intern Med. 1983 Jan;143(1):85-7
pubmed: 6849611
Mult Scler. 2015 Jun;21(7):866-874
pubmed: 25344373
Glia. 1988;1(6):366-70
pubmed: 2976396
J Neuroinflammation. 2018 Mar 19;15(1):88
pubmed: 29554927
J Neuroinflammation. 2017 Aug 29;14(1):171
pubmed: 28851393
JAMA Neurol. 2014 Mar;71(3):276-83
pubmed: 24425068
J Neurol Neurosurg Psychiatry. 2008 Oct;79(10):1134-6
pubmed: 18270237
Arch Neurol. 2007 Jun;64(6):899-901
pubmed: 17562942
Mult Scler. 2012 Jan;18(1):5-10
pubmed: 22146604
Neurology. 2012 Sep 18;79(12):1273-7
pubmed: 22914827
J Neuroinflammation. 2011 Dec 28;8:184
pubmed: 22204662
J Neuroinflammation. 2016 Sep 26;13(1):279
pubmed: 27788675
JAMA Neurol. 2018 Jan 1;75(1):65-71
pubmed: 29131884
Cerebrospinal Fluid Res. 2005 Jun 27;2:3
pubmed: 15982411
J Cereb Blood Flow Metab. 1989 Jun;9(3):381-7
pubmed: 2497112
Arch Neurol. 2007 Jun;64(6):901-3
pubmed: 17562943
Mult Scler. 1998 Jun;4(3):111-7
pubmed: 9762657
Autoimmun Rev. 2016 Apr;15(4):307-24
pubmed: 26708342
Neurology. 2006 May 23;66(10):1485-9
pubmed: 16717206
J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):446-51
pubmed: 9343121
Arch Neurol. 2007 Jun;64(6):906
pubmed: 17562945
Ann Neurol. 2018 Aug;84(2):315-328
pubmed: 30014603
Medicine (Baltimore). 2004 Sep;83(5):280-91
pubmed: 15342972
J Neuroinflammation. 2018 May 3;15(1):134
pubmed: 29724224
Arch Neurol. 2010 Oct;67(10):1201-8
pubmed: 20937947
Mult Scler. 1998 Jun;4(3):99-107
pubmed: 9762655
J Neurol Sci. 2009 May 15;280(1-2):98-100
pubmed: 19041103
J Neurol Sci. 2011 Jul 15;306(1-2):82-90
pubmed: 21550068
Lancet Neurol. 2016 Mar;15(3):317-31
pubmed: 26724102
J Neurosci. 2006 Mar 22;26(12):3220-8
pubmed: 16554473
J Neuroinflammation. 2016 Sep 27;13(1):280
pubmed: 27793206
J Neuroinflammation. 2010 Sep 08;7:52
pubmed: 20825655
J Neuroinflammation. 2019 Feb 28;16(1):51
pubmed: 30819213
J Neurol Neurosurg Psychiatry. 1994 Aug;57(8):897-902
pubmed: 8057110
Mult Scler. 2011 Sep;17(9):1067-73
pubmed: 21543553
J Neurol. 2016 Jul;263(7):1349-60
pubmed: 27147513

Auteurs

Sven Jarius (S)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany. sven.jarius@med.uni-heidelberg.de.

Hannah Pellkofer (H)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.

Nadja Siebert (N)

Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, and Charité Universitätsmedizin Berlin, Berlin, Germany.

Mirjam Korporal-Kuhnke (M)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.

Martin W Hümmert (MW)

Department of Neurology, Hannover Medical School, Hannover, Germany.
Department of Clinical Neuroimmunology and Neurochemistry, Hannover Medical School, Hannover, Germany.

Marius Ringelstein (M)

Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Department of Neurology, Center for Neurology and Neuropsychiatry, LVR-Klinikum, Heinrich Heine University, Düsseldorf, Germany.

Paulus S Rommer (PS)

Institute of Neurology, Medical University of Vienna, Vienna, Austria.

Ilya Ayzenberg (I)

Department of Neurology, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany.

Klemens Ruprecht (K)

Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Luisa Klotz (L)

Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.

Nasrin Asgari (N)

Department of Regional Health Research, Odense, Denmark.
Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.

Tobias Zrzavy (T)

Institute of Neurology, Medical University of Vienna, Vienna, Austria.

Romana Höftberger (R)

Institute of Neurology, Medical University of Vienna, Vienna, Austria.

Rafik Tobia (R)

Department of Neuropathology, University of Göttingen, Göttingen, Germany.

Mathias Buttmann (M)

Caritas Hospital Bad Mergentheim, Bad Mergentheim, Germany.

Kai Fechner (K)

Euroimmun AG, Lübeck, Germany.

Kathrin Schanda (K)

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Martin Weber (M)

Department of Neuropathology, University of Göttingen, Göttingen, Germany.

Susanna Asseyer (S)

Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, and Charité Universitätsmedizin Berlin, Berlin, Germany.

Jürgen Haas (J)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.

Christian Lechner (C)

Division of Pediatric Neurology, Department of Pediatrics I, Medical University of Innsbruck, Innsbruck, Austria.

Ingo Kleiter (I)

Department of Neurology, St Josef Hospital, Ruhr-University Bochum, Bochum, Germany.
Marianne-Strauß-Klinik, Behandlungszentrum Kempfenhausen für Multiple Sklerose Kranke gGmbH, Berg, Germany.

Orhan Aktas (O)

Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.

Corinna Trebst (C)

Department of Neurology, Hannover Medical School, Hannover, Germany.

Kevin Rostasy (K)

Department of Pediatric Neurology, Children's Hospital Datteln, University Witten/Herdecke, Witten, Germany.

Markus Reindl (M)

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

Tania Kümpfel (T)

Institute of Clinical Neuroimmunology, University Hospital and Biomedical Center, Ludwig-Maximilians University Munich, Munich, Germany.

Friedemann Paul (F)

Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine, and Charité Universitätsmedizin Berlin, Berlin, Germany.

Brigitte Wildemann (B)

Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH